VEGF Inhibitors
Jul 28, 2026
Ultomiris Phase III Trial Update Highlights Progress in Post-Transplant TMA; argenx Acquires Forte Biosciences; Otsuka’s SIMTRIYO Receives FDA Nod as a First-in-Class ADHD Treatment; Outlook Therapeutics Secures FDA Approval for LYTENAVA to Treat Wet AMD; Merck Reveals Future Access Strategy for Once-Monthly Oral HIV Prevention Therapy Alimatravir
Phase III Ultomiris Trial Reports Progress in Adults and Adolescents with HSCT-Related TMA Topline findings from the Phase III ALXN1210-TMA-313 trial indicated that Ultomiris (ravulizumab) did not meet the primary endpoint of event-free survival over 26 weeks versus placebo in adults and adolescents (12 years an...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
